{"id":125995,"date":"2026-07-09T07:57:41","date_gmt":"2026-07-09T07:57:41","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/125995\/"},"modified":"2026-07-09T07:57:41","modified_gmt":"2026-07-09T07:57:41","slug":"novo-nordisk-cpsenovo-b-teams-up-with-vivani-to-test-a-semaglutide-implant","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/125995\/","title":{"rendered":"Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. <\/p>\n

Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani’s NanoPortal platform for chronic weight management. <\/p>\n

Vivani has initiated a Phase 1 clinical study of the implant, while Novo Nordisk assesses semaglutide in this drug delivery format. <\/p>\n

The partnership focuses on an implantable GLP-1 approach that could offer an alternative to pills and injections for obesity treatment. <\/p>\n

Novo Nordisk, traded as CPSE:NOVO B, is already a central player in GLP-1 treatments, and this implant project adds another angle to its obesity care toolkit. The share price currently sits at DKK327.45, with the stock up 4.1% over the past week and 15.4% over the past month. Over longer periods, returns have been mixed, including a decline of 23.9% over the past year and 31.6% over three years, while the five year return stands at 33.4%. <\/p>\n

For investors watching obesity treatments, this collaboration highlights Novo Nordisk’s focus on alternative delivery methods that could support treatment consistency and convenience. The Phase 1 study and Novo Nordisk’s evaluation activity may be worth tracking as one more indicator of how the company is positioning its GLP-1 portfolio within a competitive weight management drug market. <\/p>\n

Stay updated on the most important news stories for Novo Nordisk<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novo Nordisk. <\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B Earnings & Revenue Growth as at Jul 2026 <\/p>\n

3 things going right for Novo Nordisk that this headline doesn’t cover.<\/a> <\/p>\n

The Vivani partnership gives Novo Nordisk another way to extend its semaglutide franchise beyond the existing Wegovy injections and tablets that are already supported by the Medicare GLP-1 Bridge. While Wegovy is available through that program at a reported $50 monthly copay for eligible Medicare patients, treatment still depends on regular dosing and prescription renewals. An implant based on Vivani’s NanoPortal technology could, if successful, support long term dosing from a single procedure, which may appeal to patients who struggle with adherence or do not want frequent injections. For investors, this ties drug delivery more tightly to Novo Nordisk’s broader push on access and authenticity, where it is working with CMS, pharmacists, and telehealth channels to keep patients within regulated supply. It also sits alongside a competitive field that includes Eli Lilly and newer GLP-1 developers, where differentiation is not only about efficacy but also convenience, safety profile, and how easily payers can manage long term therapy. <\/p>\n

How This Fits Into The Novo Nordisk Narrative <\/p>\n

The Vivani implant concept supports the existing narrative that Novo Nordisk is expanding its obesity and diabetes reach through new product formats, alongside Wegovy injections, oral tablets, and capacity investments in places like Athlone. <\/p>\n

A long acting implant could complicate the narrative that weekly treatments remain the core earnings engine, because it introduces a different dosing model that may shift how revenue and costs are spread over time. <\/p>\n

The narrative focuses on product launches, manufacturing expansion, and reimbursement, but does not fully address how implantable GLP-1 devices might change competitive dynamics with companies such as Eli Lilly or future GLP-1 entrants. <\/p>\n

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk<\/a> to help decide what it’s worth to you. <\/p>\n

The Risks and Rewards Investors Should Consider <\/p>\n

\u26a0\ufe0f A new implant delivery route brings clinical and regulatory risk, including potential safety findings in Phase 1 and later trials that could limit use compared with more familiar pills and injections. <\/p>\n

\u26a0\ufe0f If payers such as Medicare are cautious about reimbursing higher procedure based costs, uptake of an implant could be slower than for Wegovy injections and tablets that already have a defined access pathway. <\/p>\n

\ud83c\udf81 Success with an implantable GLP-1 format could widen Novo Nordisk’s reach in chronic weight management by offering an option for patients who prefer less frequent dosing or have adherence challenges. <\/p>\n

\ud83c\udf81 Working with Vivani on NanoPortal implants strengthens Novo Nordisk’s drug delivery toolkit in a crowded GLP-1 market that includes Eli Lilly and other developers, which may support its position as a key obesity treatment provider. <\/p>\n

What To Watch Going Forward <\/p>\n

Following this news, investors can watch for early data from Vivani’s Phase 1 study of the semaglutide implant, any comments from Novo Nordisk on how it views the long term role of implants alongside Wegovy injections and tablets, and signals on payer interest in procedure based GLP-1 delivery. It is also worth tracking how competitors such as Eli Lilly or newer GLP-1 companies respond in terms of alternative delivery formats and how regulators approach reimbursement and safety for long acting obesity treatments. <\/p>\n

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk<\/a> to never miss an update on the top community narratives. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":125996,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[16178,272,1442,60940,60953,317],"class_list":["post-125995","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-drug-delivery","tag-novo-nordisk","tag-obesity-treatment","tag-vivani","tag-vivani-medical","tag-weight-management"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116888957567476657","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/125995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=125995"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/125995\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/125996"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=125995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=125995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=125995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}